Alkermes plc (NASDAQ:ALKS - Free Report) - Equities research analysts at Zacks Research reduced their Q1 2025 earnings per share estimates for shares of Alkermes in a report issued on Wednesday, April 9th. Zacks Research analyst R. Department now expects that the company will post earnings of $0.28 per share for the quarter, down from their prior estimate of $0.29. The consensus estimate for Alkermes' current full-year earnings is $1.31 per share. Zacks Research also issued estimates for Alkermes' Q2 2025 earnings at $0.34 EPS, FY2025 earnings at $1.33 EPS, Q2 2026 earnings at $0.33 EPS, Q4 2026 earnings at $0.43 EPS, FY2026 earnings at $1.24 EPS and FY2027 earnings at $1.14 EPS.
Other research analysts have also issued research reports about the company. Royal Bank of Canada assumed coverage on Alkermes in a research report on Thursday, March 13th. They set a "sector perform" rating and a $40.00 target price for the company. Deutsche Bank Aktiengesellschaft boosted their price objective on Alkermes from $40.00 to $52.00 and gave the company a "buy" rating in a report on Thursday, March 27th. HC Wainwright reiterated a "neutral" rating and issued a $46.00 target price on shares of Alkermes in a research note on Thursday, February 13th. StockNews.com raised shares of Alkermes from a "buy" rating to a "strong-buy" rating in a research note on Thursday, February 13th. Finally, The Goldman Sachs Group upped their price target on shares of Alkermes from $30.00 to $32.00 and gave the stock a "buy" rating in a report on Friday, February 14th. Four equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $38.50.
Get Our Latest Stock Report on Alkermes
Alkermes Stock Down 0.5 %
NASDAQ:ALKS traded down $0.15 during mid-day trading on Monday, hitting $27.05. 1,699,443 shares of the stock traded hands, compared to its average volume of 1,754,787. Alkermes has a 52 week low of $22.90 and a 52 week high of $36.45. The stock has a market capitalization of $4.46 billion, a price-to-earnings ratio of 12.47, a PEG ratio of 2.20 and a beta of 0.39. The firm's 50 day moving average is $32.73 and its two-hundred day moving average is $30.42.
Alkermes (NASDAQ:ALKS - Get Free Report) last posted its quarterly earnings data on Wednesday, February 12th. The company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.81 by $0.11. Alkermes had a net margin of 23.57% and a return on equity of 30.80%.
Insider Activity
In other news, EVP Craig C. Hopkinson sold 144,419 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $35.53, for a total transaction of $5,131,207.07. Following the transaction, the executive vice president now directly owns 57,875 shares in the company, valued at approximately $2,056,298.75. This trade represents a 71.39 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.89% of the company's stock.
Institutional Trading of Alkermes
A number of hedge funds have recently bought and sold shares of the stock. Venturi Wealth Management LLC bought a new position in shares of Alkermes in the 4th quarter worth $25,000. EverSource Wealth Advisors LLC raised its holdings in Alkermes by 106.2% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,635 shares of the company's stock worth $47,000 after purchasing an additional 842 shares in the last quarter. Blue Trust Inc. raised its holdings in Alkermes by 2,231.5% in the fourth quarter. Blue Trust Inc. now owns 1,702 shares of the company's stock worth $49,000 after purchasing an additional 1,629 shares in the last quarter. USA Financial Formulas purchased a new stake in shares of Alkermes during the first quarter valued at about $49,000. Finally, Fifth Third Bancorp boosted its holdings in shares of Alkermes by 54.4% in the 1st quarter. Fifth Third Bancorp now owns 1,479 shares of the company's stock valued at $49,000 after buying an additional 521 shares in the last quarter. Hedge funds and other institutional investors own 95.21% of the company's stock.
About Alkermes
(
Get Free Report)
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Featured Stories
Before you consider Alkermes, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alkermes wasn't on the list.
While Alkermes currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
